Ernexa Therapeutics Inc.
ERNA
$1.39
-$0.10-6.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.71% | -101.29% | -105.55% | -124.62% | -10.08% |
| Total Depreciation and Amortization | -69.63% | -27.22% | 45.86% | 181.73% | 537.65% |
| Total Amortization of Deferred Charges | 255.16% | 543.58% | 1,635.64% | 4,513.46% | -- |
| Total Other Non-Cash Items | 1,394.69% | 1,266.14% | 1,118.91% | 2,334.23% | 486.53% |
| Change in Net Operating Assets | -334.24% | -895.63% | 6.71% | 97.23% | 621.81% |
| Cash from Operations | 12.53% | 21.83% | 22.40% | 19.97% | 23.19% |
| Capital Expenditure | 94.85% | -123.33% | -1,842.11% | -1,747.62% | -476.56% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -97.33% | -97.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.79% | -131.03% | -1,821.05% | -397.67% | -524.42% |
| Total Debt Issued | -68.38% | -68.38% | -70.60% | 67.30% | -- |
| Total Debt Repaid | -- | -- | -- | -149,900.00% | -74,900.00% |
| Issuance of Common Stock | -- | 256.56% | 255.31% | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | 50.00% | 50.00% | 0.00% | 0.00% |
| Other Financing Activities | 52.63% | 45.02% | 32.67% | 61.54% | -156.76% |
| Cash from Financing | -31.39% | -60.26% | -62.19% | -21.23% | 122.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -415.89% | -2,495.37% | -156.81% | 4.90% | 105.56% |